

## DAFTAR PUSTAKA

1. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Global cancer observatory: cancer today – China. Lyon, France: IARC; 2022 [cited 2025 Mar 2]. Available from: <https://gco.iarc.fr/>
2. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Global cancer observatory: cancer today – Malaysia. Lyon, France: IARC; 2022 [cited 2025 Mar 2]. Available from: <https://gco.iarc.fr/>
3. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Global cancer observatory: cancer today – Indonesia. Lyon, France: IARC; 2022 [cited 2025 Mar 2]. Available from: <https://gco.iarc.fr/>
4. Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Rodríguez-Abreu D, et al. Comparison of clinical and genetic characteristics between younger and older lung cancer patients. Arch Bronconeumol. 2023 Feb; 60(3):123–9
5. Andarini S, Syahruddin E, Aditya N, Zaini J, Kurniawan FD, Ermayanti S, et al. Indonesian Society of Respirology (ISR) consensus statement on lung cancer screening and early detection in indonesia. Jurnal Respirologi Indonesia. 2023 Apr 19;43(2):144–50.
6. Polanco D, Pinilla L, Gracia-Lavedan E, Mas A, Bertran S, Fierro G, et al. Prognostic value of symptoms at lung cancer diagnosis: A three-year observational study. J Thorac Dis. 2021 Mar 1;13(3):1485–94.
7. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. Vol. 17, Journal of Thoracic Oncology. Elsevier Inc.; 2022. p. 362–87.
8. Pradnyaandara igbma, shdisi. Karakteristik pasien karsinoma paru di RSUP Sanglah Denpasar tahun 2017-2018. Jurnal medika udayana. 2021;10:81–5.
9. Robbins SL, Cotran RS. Buku ajar patologi Robbins. Edisi Internasional. Philadelphia: Elsevier Saunders; 2013. ISBN: 978-1-4377-1781-5
10. Tomassini S, Falcionelli N, Sernani P, Burattini L, Dragoni AF. Lung nodule diagnosis and cancer histology classification from computed tomography data by convolutional neural networks: A survey. Vol. 146, Computers in Biology and Medicine. Elsevier Ltd; 2022.
11. Tang M, Abbas HA, Negrao M V., Ramineni M, Hu X, Hubert SM, et al. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 Dec 1;12(1).

12. Mescher AL, Junqueira LCU. Junqueira's basic histology : text and atlas.
13. Wadowska K, Bil-Lula I, Trembecki Ł, Śliwińska-Mossoń M. Genetic markers in lung cancer diagnosis: A review. Vol. 21, International Journal of Molecular Sciences. MDPI AG; 2020. p. 1–24.
14. Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Vol. 22, International Journal of Molecular Sciences. MDPI AG; 2021.
15. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Global cancer observatory: cancer today – lung cancer. Lyon, France: IARC; 2022 [cited 2025 Mar 2]. Available from: <https://gco.iarc.fr/>
16. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Global cancer observatory: cancer today – Canada. Lyon, France: IARC; 2022 [cited 2025 Mar 2]. Available from: <https://gco.iarc.fr/>
17. International Agency for Research on Cancer (IARC), World Health Organization (WHO). Global cancer observatory: cancer today – Singapore. Lyon, France: IARC; 2022 [cited 2025 Mar 2]. Available from: <https://gco.iarc.fr/>
18. Ramadhaniah F, Suzanna E, Syahruddin E, Shalmont G, Rahayu PS. National lung cancer screening: recommended age for screening. Indonesian journal of cancer [internet]. 2024 Dec 23;18(4):517–22. Available from: <https://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/1223>
19. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Vol. 25, Wspolczesna Onkologia. Termedia Publishing House Ltd.; 2021. p. 45–52.
20. ALQudah MA, ALFaqih MA, Hamouri S, Al-Shaikh AF, Haddad HK, Al-Quran WY, et al. Epidemiology and histopathological classification of lung cancer: A study from Jordan, retrospective observational study. Annals of Medicine and Surgery. 2021 May 1;65.
21. Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. cancer epidemiology biomarkers and prevention. 2019;28(10):1563–79.
22. Hoeng J, Maeder S, Vanscheeuwijck P, Peitsch MC. Assessing the lung cancer risk reduction potential of candidate modified risk tobacco products. Intern Emerg Med. 2019 Sep 1;14(6):821–34.

23. Ma B, Stepanov I, Hecht SS. Recent studies on DNA adducts resulting from human exposure to tobacco smoke. Vol. 7, Toxics. MDPI AG; 2019.
24. Janes SM, Campbell PJ. Tobacco exposure and somatic mutations in normal human bronchial epithelium Europe PMC Funders Group. Nature [Internet]. 2020;578(7794):266–72. Available from: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms) <http://dx.doi.org/10.17632/b53h2kwpwy.2>.
25. Mulyawan E, Setiawan JA. The correlation between smoking cumulative dose based on Brinkman Index with peak expiratory flow rate. J Gen Fam Med. 2024 Jul 1;25(4):193–7.
26. Rusmaully J, Tvardik N, Martin D, Billmann R, Cénée S, Antoine M, et al. Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study). BMC Cancer. 2021 Dec 1;21(1).
27. Khaddour K, Jonna S, Deneka A, Patel JD, Abazeed ME, Golemis E, et al. Targeting the epidermal growth factor receptor in egfr-mutated lung cancer: Current and emerging therapies. Vol. 13, Cancers. MDPI AG; 2021.
28. Minchin S, Lodge J. Understanding biochemistry: Structure and function of nucleic acids. Vol. 63, Essays in Biochemistry. Portland Press Ltd; 2019. p. 433–56.
29. Yousefzadeh M, Henpita C, Vyas R, Soto-Palma C, Robbins P, Niedernhofer L. DNA damage—how and why we age? elife. 2021 Jan 1;10:1–17.
30. Prasad RR, Mishra DK, Kumar M, Yadava PK. Human telomerase reverse transcriptase promotes the epithelial to mesenchymal transition in lung cancer cells by enhancing c-MET upregulation. Heliyon. 2022 Jan 1;8(1).
31. Boccardi V, Marano L. Aging, Cancer, and Inflammation: The telomerase connection. Vol. 25, International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2024.
32. Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Vol. 122, British Journal of Cancer. Springer Nature; 2020. p. 943–52.
33. Florez N, Kiel L, Riano I, Patel S, DeCarli K, Dhawan N, et al. Lung Cancer in women: the past, present, and future. Vol. 25, Clinical Lung Cancer. Elsevier Inc.; 2024. p. 1–8.
34. Ramadhani N, Soeroso NN, Tarigan SP, Eyanoer PC, Hidayat H. Correlation between genetic polymorphism of CYP2A13 genotype and lung cancer in female passive smokers. Molecular and Cellular Biomedical Sciences. 2022 Jul

5;6(2):89.

35. May L, Shows K, Nana-Sinkam P, Li H, Landry JW. Sex differences in lung cancer. Vol. 15, Cancers. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
36. Gawełko J, Cierpiał-Wolan M, Bwanakare S, Czarnota M. Association between air pollution and squamous cell lung cancer in South-Eastern Poland. *Int J Environ Res Public Health*. 2022 Sep 1;19(18).
37. Kyung SY, Jeong SH. Particulate-matter related respiratory diseases. Vol. 83, Tuberculosis and Respiratory Diseases. Korean National Tuberculosis Association; 2020. p. 116–21.
38. Kussainova A, Bulgakova O, Aripova A, Khalid Z, Bersimbaev R, Izzotti A. The role of mitochondrial mirnas in the development of radon-induced lung cancer. Vol. 10, Biomedicines. MDPI; 2022.
39. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, etiology, and prevention. Vol. 41, Clinics in Chest Medicine. W.B. Saunders; 2020. p. 1–24.
40. Mravec B, Tibensky M, Horvathova L, Babal P. E-cigarettes and cancer risk. Vol. 13, Cancer Prevention Research. American Association for Cancer Research Inc.; 2020. p. 137–43.
41. Budisan L, Zanoaga O, Braicu C, Pirlog R, Covaliu B, Esanu V, et al. Links between infections, lung cancer, and the immune system. *Int J Mol Sci*. 2021 Sep 1;22(17).
42. Qi C, Sun SW, Xiong XZ. From COPD to lung cancer: mechanisms linking, diagnosis, treatment, and prognosis. Vol. 17, International Journal of COPD. Dove Medical Press Ltd; 2022. p. 2603–21.
43. Kantor ED, Hsu M, Du M, Signorello LB. Allergies and asthma in relation to cancer risk. *Cancer Epidemiology Biomarkers and Prevention*. 2019;28(8):1395–403.
44. Castaldo N, Fantin A, Manera M, Patruno V, Sartori G, Crisafulli E. Do patients with bronchiectasis have an increased risk of developing lung cancer? A Systematic Review. Vol. 13, Life. MDPI; 2023.
45. Wei X, Zhu C, Ji M, Fan J, Xie J, Huang Y, et al. Diet and risk of incident lung cancer: a large prospective cohort study in UK Biobank. *American Journal of Clinical Nutrition*. 2021 Dec 1;114(6):2043–51.
46. Shi YX, Sheng DQ, Cheng L, Song XY. Current landscape of epigenetics in lung cancer: focus on the mechanism and application. Vol. 2019, *Journal of Oncology*. Hindawi Limited; 2019.

47. Nasim F, Sabath BF, Eapen GA. Lung cancer. Vol. 103, Medical Clinics of North America. W.B. Saunders; 2019. p. 463–73.
48. Singer ED, Faiz SA, Qdaisat A, Abdeldaem K, Dagher J, Chaftari P, et al. Hemoptysis in cancer patients. Vol. 15, Cancers. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
49. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023 Nov;73(6):620–52.
50. Harle ASM, Blackhall FH, Molassiotis A, Yorke J, Dockry R, Holt KJ, et al. Cough in patients with lung cancer: a longitudinal observational study of characterization and clinical associations. Chest. 2019 Jan 1;155(1):103–13.
51. Galvez-Nino M, Ruiz R, Pinto JA, Roque K, Mantilla R, Raez LE, et al. Lung cancer in the young. Lung. 2020 Feb 1;198(1):195–200.
52. Ruano-Raviña A, Provencio M, Calvo De Juan V, Carcereny E, Moran T, Rodriguez-Abreu D, et al. Lung cancer symptoms at diagnosis: Results of a nationwide registry study. ESMO Open. 2020 Nov 19;5(6).
53. Jeffrey Kim M, Hobart Lee M, Brian W. Huang M. Lung cancer: diagnosis, treatment principles, and screening. In Loma Linda University School of Medicine, Loma Linda, California: American Academy of Family Physicians; 2022. p. 487–94.
54. Kim J, Lee HM, Huang BW. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician. 2022;105(5):487-494.
55. Momozane T, Shigetsu K, Kimura Y, Kishima H, Kodama K. The histological diagnosis and molecular testing of lung cancer by surgical biopsy for intrathoracic lesions. Gen Thorac Cardiovasc Surg. 2021 Aug 1;69(8):1185–91.
56. Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. Vol. 15, Journal of Thoracic Oncology. Elsevier Inc; 2020. p. 709–40.
57. Panunzio A, Sartori P. Lung cancer and radiological imaging. Curr Radiopharm. 2020 May 23;13(3):238–42.
58. Riquelme D, Akhloufi MA. Deep learning for lung cancer nodules detection and classification in CT scans. Vol. 1, AI (Switzerland). Multidisciplinary Digital Publishing Institute (MDPI); 2020. p. 28–67.

59. Farsad M. FDG PET/CT in the staging of lung cancer. *Curr Radiopharm*. 2019 Dec 23;13(3):195–203.
60. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Vol. 94, Mayo Clinic Proceedings. Elsevier Ltd; 2019. p. 1623–40.
61. Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. *Cancers (Basel)*. 2021 Sep 1;13(18).
62. Berezowska S, Maillard M, Keyter M, Bisig B. Pulmonary squamous cell carcinoma and lymphoepithelial carcinoma – morphology, molecular characteristics and differential diagnosis. Vol. 84, Histopathology. John Wiley and Sons Inc; 2024. p. 32–49.
63. Liu Y, Zhu Y, Zhu Y, Bai L, Chen F, Wang J, et al. Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma. *BMC Cancer*. 2020 Jun 5;20(1).
64. Kutob L, Schneider F. Lung cancer staging. Vol. 13, *Surgical Pathology Clinics*. W.B. Saunders; 2020. p. 57–71.
65. Hwang JK, Page BJ, Flynn D, Passmore L, McCaul E, Brady J, et al. Validation of the eighth edition TNM lung cancer staging system. *Journal of Thoracic Oncology*. 2020 Apr 1;15(4):649–54.
66. Feng SH, Yang ST. The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with ct image demonstrations. Vol. 25, *Diagnostic and Interventional Radiology*. AVES; 2019. p. 270–9.
67. Alfarisa S, Wahyuni S. Karakteristik pasien kanker paru di RSUP Dr. M. Djamil Padang tahun 2021 [Internet]. Available from: <http://journal.scientic.id/index.php/sciena/issue/view/14>
68. Sanford NN, Sher DJ, Butler S, Xu X, Ahn C, D'Amico A V., et al. Cancer screening patterns among current, former, and never smokers in the United States, 2010-2015. Vol. 2, *JAMA Network Open*. American Medical Association; 2019.
69. Faradisa E. Analisis faktor risiko pada penyakit kanker paru berdasarkan rekam medis rawat inap di Rumah Sakit Umum Daerah Dr. Moewardi Surakarta [Internet]. sipora.polije.ac.id; 2024 [cited 2025 May 7]. Available from: <https://sipora.polije.ac.id>

70. Ainun, Wiriansya EP, Karim M, Syahril E, Kanang ILD, Ahmad AI. Profil penderita adenokarsinoma paru di RS. Ibnu Sina Makassar periode Januari 2016-Mei 2019. Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran [Internet]. 2021 Dec [cited 2025 May 7];1(3). Available from: <https://fmj.fk.umi.ac.id/index.php/fmj>
71. Fidler-Benaoudia MM, Torre LA, Bray F, Ferlay J, Jemal A. Lung cancer incidence in young women vs. young men: A systematic analysis in 40 countries. *Int J Cancer.* 2020 Aug 1;147(3):811–9.
72. Koswara T, Iriawan J, Surya F. Karakteristik karsinoma paru bukan sel kecil dan hasil pemeriksaan EGFR di RSUP Dr. Hasan Sadikin periode tahun 2018-2020. *Medika Kartika: Jurnal Kedokteran dan Kesehatan.* 2022;5(2):150-161.
73. Afriani. Karakteristik penderita adenokarsinoma paru di RS Wahidin Sudirohusodo priode Juni 2018 - Juni 2019 [Skripsi]. Makassar: Fakultas Kedokteran, Universitas Hasanudin; 2020.

